RSLBF (RaySearch Laboratories AB) Notes Receivable: $0.0 Mil (As of Mar. 2026)


RSLBF RaySearch Laboratories AB RSLBF
92 GF Score
Price $21.17
GF Value $20.80
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Notes Receivable?

RaySearch Laboratories AB RSLBF +0.81% 92 Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus rates RSLBF with a GF Score™ of 92/100 and a GF Value™ of $20.80 (Fairly Valued). The stock has 2 warning signs investors should review.

RaySearch Laboratories AB's Notes Receivable for the quarter that ended in Mar. 2026 was $0.0 Mil.

RaySearch Laboratories AB Notes Receivable Related Terms

RaySearch Laboratories AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Notes Receivable Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RSLBF
92GF Score
RaySearch Laboratories AB RSLBF
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
RaySearch Laboratories AB (RSLBF) has a Notes Receivable of $0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Notes Receivable too high?
RaySearch Laboratories AB's current Notes Receivable is $0.0 Mil. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Notes Receivable compare to VEEV and BTSG?
RaySearch Laboratories AB's Notes Receivable of $0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $20.80, compared to a current price of $21.17 — trading 1.8% above its estimated fair value. The current Notes Receivable is $0.0 Mil. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of $21.17 is trading 1.8% above its estimated GF Value™ of $20.80. GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.

Key valuation signals for RSLBF:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $20.80 vs. price of $21.17 (1.8% above fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score

Get the complete analysis for RSLBF

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.17
Price
$20.80
GF Value